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Summary 
 
Hepatocyte growth factor (HGF) and Met/HGF receptor tyrosine kinase play a role in the 
progression to invasive and metastatic cancers. A variety of cancer cells secrete molecules 
that enhance HGF expression in stromal fibroblasts, while fibroblast-derived HGF, in turn, is 
a potent stimulator of the invasion of cancer cells. In addition to the ligand-dependent 
activation, Met receptor activation is negatively regulated by cell-cell contact and Ser985 
phosphorylation in the juxtamembrane of Met. The loss of intercellular junctions may 
facilitate an escape from the cell-cell contact-dependent suppression of Met-signaling. 
Significance of juxtamembrane mutations found in human cancers is assumed to be a 
loss-of-function in the negative regulation of Met. In attempts to block the malignant 
behavior of cancers, NK4 was isolated as a competitive antagonist against HGF-Met 
signaling. Independently on its HGF-antagonist action, NK4 inhibited angiogenesis induced 
by vascular endothelial cell growth factor and basic fibroblast growth factor, as well as HGF. 
In experimental models of distinct types of cancers, NK4 inhibited Met activation and this 
was associated with inhibition of tumor invasion and metastasis. NK4 inhibited tumor 
angiogenesis, thereby suppressing angiogenesis-dependent tumor growth. Cancer treatment 
with NK4 suppresses malignant tumors to be ‘static’ in both tumor growth and spreading.  
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1 Introduction 
 Among malignant behavior of tumors, tumor metastasis is the most important factor 
affecting survival of cancer patients. If metastatic tumors can be suppressed to 
non-metastatic tumors, the rate of cancer cures is considered to show much improvement. 
The dissociation and migration of tumor cells, adhesive interaction of cancer cells towards 
the extracellular matrix, and proteolysis of extracellular matrix proteins play a definitive role 
in tumor invasion and metastasis. Although mutational alterations that occur in oncogenes 
and tumor suppressor genes are of a genetical background for tumorigenic transformation of 
cells, invasive and metastatic behavior of tumor cells is largely regulated by extracellularly 
acting growth factors. Among them, hepatocyte growth factor (HGF) particularly affects 
metastatic behavior in a wide variety of cancer cells [1-3].  
 HGF was first identified and cloned as a mitogenic polypeptide for hepatocytes [4-6]. 
The receptor for HGF is a c-met protooncogene product of transmembrane tyrosine kinase [7, 
8]. HGF is involved in development and morphogenesis of embryonic tissues, while in 
mature tissues HGF plays roles in regeneration and protection of various tissues, including 
the liver [9, 10]. HGF has angiogenic and lymphangiogenic activities respectively for 
vascular and lymphatic endothelial cells [11-14]. In tumor tissues, however, tumor cells 
utilize the biological actions of HGF for their invasive and metastatic behavior. HGF 
stimulates 1) the dissociation of cancer cells at the primary site, 2) invasion through the 
basement membrane and host stroma by enhancing cell-matrix interactions, protease 
networks for the breakdown of extracellular matrix proteins, and motogenic responses [1-3]. 
Angiogenic and lymphangiogenic activities of HGF may facilitate cancer metastasis. Thus, 
the abrogation of HGF-Met receptor coupling or Met receptor-mediated signaling events is a 
strategy toward prevention of tumor metastasis.  
 NK4 was isolated as a competitive antagonist for HGF and the Met receptor, and 
subsequent studies showed that NK4 is bifunctional: it is an HGF-antagonist and an 
angiogenesis inhibitor [15-17]. NK4 can be considered for use in cancer treatment by 
targeting the malignant behavior of tumor cells, rather than by direct killing of the tumor 
cells. This review focuses on tumor invasion and metastasis regulated by the HGF-Met 
system and experimental cancer treatment with NK4.  
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2 HGF-Met in tumor-stromal interactions 
 Stromal components associated with carcinoma cells are composed of extracellular 
matrix and distinct types of cells, including those comprising the vasculature (endothelial 
cells, pericytes, and smooth muscle cells), inflammatory cells (lymphocytes, neutrophils, and 
macrophages), fibroblasts, and tumor (or carcinoma) -associated fibroblasts with 
myofibroblast-like characteristic. Host stromal influence on epithelial neoplasia, tumor 
angiogenesis and malignant behavior in carcinomas are evident in various types of cancers, 
including prostate, stomach, skin, oral cavity, mammary gland, and colon cancers [18, 19]. 
Recombinant grafts in which non-tumorigenic epithelial cells are combined with particular 
cancer-associated fibroblasts induce tumorigenic progression [20]. Recent studies have 
demonstrated that experimentally induced genetic alterations, i.e., inactivation of 
transforming growth factor-β type II receptor gene, in stromal fibroblasts induce epithelial 
neoplasia and invasive carcinoma [21].  
 The stromal cells participate in not only neoplastic transformation but also tumor 
invasion and metastasis. The involvement of stromal fibroblast-derived factor in the invasion 
of carcinoma cells was first demonstrated using oral squamous cell carcinoma cells cultured 
on a collagen gel [22]. When the cancer cells were cultured alone, no invasion was observed, 
whereas they invaded collagen gels in which fibroblasts were incorporated or when 
fibroblast-derived conditioned medium was added to the culture. These findings indicate that 
fibroblast-derived soluble factor is responsible for the induction of invasive behavior in oral 
squamous cell carcinoma. The factor was later shown to be HGF [23]. When cancer cells 
were cultured in collagen gels, HGF induced dissociation and invasion of cancer cells, 
whereas epidermal growth factor had marginal effect on invasive behavior of these cancer 
cells (Fig. 1A).  
 The enhancement of migration and invasion of cancer cells in the presence of stromal 
fibroblasts was further demonstrated in a variety of cancer cells, including squamous cell 
carcinoma cells, breast carcinoma, gallbladder carcinoma, esophageal cancer, and prostate 
cancer [24-26]. In these studies, the enhancement in cancer cell invasion by co-cultivation 
with fibroblasts was inhibited by NK4, a specific competitive antagonist against HGF-Met 
(see below for details) or a neutralizing antibody against HGF. The induction and 
enhancement of cancer cell invasion by HGF has been demonstrated in a wide variety of 
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cancer cells [27]. These results indicate that the invasion of various cancer cells is enhanced 
by fibroblast-derived factors and that HGF is a significant factor responsible for cancer cell 
invasion mediated by tumor-stromal interactions.  
 Among various stromal cell types, fibroblasts derived from a variety of tissues express 
HGF. In addition it has been shown that vascular endothelial cells, vascular smooth muscle 
cells, neutrophils, and macrophages are cellular sources of HGF [2]. The co-expression of 
HGF and Met in several different types of carcinoma cells have been noted, however, the 
collective expression of HGF is restricted not exclusively but predominantly to stromal cells 
in a variety of carcinoma tissues. For example, in human lung adenocarcinoma tissues, a 
detailed analysis of the expression of HGF and Met using the laser-beam microdissection of 
cancer cells and tumor-associated stromal cells indicated that HGF mRNA is expressed 
exclusively in the stromal cells in different tumor samples [28]. Although the mechanisms by 
which carcinoma cells acquire the ability to express HGF are unknown, the autocrine 
activation of Met may possibly be associated with the epithelial-mesenchymal transition of 
cancer cells, a phenomenon that is occasionally observed in highly aggressive cancer cells.  
 Consistent with a lack of autonomous potential to aggressively invade into the scaffold 
of extracellular matrix in many carcinoma cells, most carcinoma cells do not secrete HGF. 
However, carcinoma cells not only receive influence of stromal-derived HGF but also 
facilitate HGF production in stromal cells. Several reports noted that the expression of HGF 
in fibroblasts in culture is enhanced by the presence of co-cultured carcinoma cells and that 
many types of carcinoma cells secrete a variety of HGF-inducers, through which HGF 
production in fibroblasts is up-regulated [24-26, 29, 30]. These carcinoma cell-derived 
HGF-inducers were identified as interleukin-1β (IL-1β), basic fibroblast growth factor 
(bFGF), platelet-derived growth factor, transforming growth factor-α and prostaglandin E2. 
These observations indicate that the presence of crosstalk between carcinoma cells and 
stromal fibroblasts, mediated by HGF and the HGF-inducers loop: carcinoma cells secrete 
HGF-inducers for stromal fibroblasts, while stromal fibroblasts secrete HGF, which in turn 
stimulates cancer cell invasion and metastasis (Fig. 1B). In addition to the role of these 
mediators that are capable of stimulating HGF expression, mediators that are expressed in 
cancer tissues are involved in modulating a microenvironment such as angiogenesis, the 
inflammatory response, and the growth of stromal cells [31-35].  
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3 Negative Regulation of Met via Cell-Cell Contact and Ser985 Phosphorylation 
 The loss of contact inhibition, the escape from growth inhibition by cell-cell contact, is 
associated with cellular transformation, which is a precursor to malignant transformation. 
Inhibition of cell proliferation by cell-cell contact is a fundamental characteristic of normal 
cells by which cellular adhesion successfully maintains highly organized tissue architecture. 
HGF-Met pathway plays roles in reconstruction/regeneration in normal and highly organized 
tissues, while invasive and metastatic behavior of cancer cells in tumor tissues. In normal 
cells, Met activation status might be regulated by not only HGF but also tissue organization 
and cell-cell contact, while in cancer cells Met activation status might be regulated by HGF 
regardless of cell-cell contact. We recently found the mechanism by which Met activation 
status is regulated through cell-cell contact, using hepatocytes in primary culture [36].  
 Proliferation of normal hepatocytes is tightly regulated by cell-cell contact. Hepatocytes 
do not undergo DNA synthesis even in the presence of excess amount of HGF when the cells 
are in tight cell-cell contact. Under the sparse condition, HGF induced prolonged Met 
tyrosine phosphorylation and a marked mitogenic response. Under the confluent condition 
wherein hepatocytes were in tight cell-cell contact, HGF induced transient Met tyrosine 
phosphorylation and failed to induce mitogenic response. The activity and expression of the 
protein tyrosine phosphatase, LAR increased specifically in confluent hepatocytes and not in 
sparse hepatocytes. LAR and Met were associated, and LAR dephosphorylated 
tyrosine-phosphorylated Met. Furthermore, specific suppression of the LAR expression 
prolonged activation of Met and released contact inhibition. Thus functional association of 
LAR and Met underlies the inhibition of Met-mediated signaling through the 
dephosphorylation of Met, which specifically occurs under the confluent condition (Fig. 
2A).  
 In addition to the regulation of Met by cell-cell contact, Met activation is regulated by 
phosphorylation of the 985th Ser (Ser985) in the Met. The juxtamembrane domain of the 
Met is consisted of highly conserved 47 amino acid residues and Ser985 resides in the 
juxtamembrane domain. Ser985 is phosphorylated by treatment of cells with 
12-O-tetradecanoylphorbol 13-acetate, an activator for protein kinase C [37]. We showed 
that Ser985 is phosphorylated by protein kinase-C and dephosphorylated by protein 
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phosphatase-2A [38]. Importantly, HGF-dependent Met tyrosine phosphorylation and 
subsequent biological responses are suppressed when Ser985 is phosphorylated. These 
results indicate that the juxtamembrane Ser985 is a negative regulatory mechanism by which 
Met activation is suppressed even if cells are stimulated by HGF.  
 Physiological significance of the negative regulatory mechanisms for 
Met-dependent signal transduction remains to be defined, however, we speculate that the 
loss-of-function in the Met negative regulation may possibly related to malignant 
progression of tumor cells. A variety of cancer cells have functional abnormalities in 
biological machineries involved in cell-cell adhesions [39]. Epithelial-mesenchymal 
transition, which occurs at boundary between tumor and stromal cells and leads to the loss of 
intercellular junctions, may facilitate an escape from the cell-cell contact-dependent 
suppression of Met-signaling. Several mutational alterations in the juxtamembrane domain 
of Met were noted in different types of human cancers [40-42]. Potential significance of the 
juxtamembrane mutations as a loss-of-function in the negative regulation of Met-dependent 
signal transduction is considerable.  
 
4 Structure and Activity of NK4 as an HGF-antagonist  
 The close involvement of the HGF-Met pathway in tumor-stromal interactions and 
cancer invasion and metastasis suggests that the HGF-Met pathway represents a potentially 
important molecular target in cancer treatment. Several lines of distinct approaches for 
inhibiting the HGF-Met pathway have been demonstrated in experimental models, including 
small molecules that inhibit the tyrosine kinase activity of the Met [43-45], ribozyme [46-48], 
small-interfering RNA (siRNA) [49, 50], neutralizing monoclonal antibodies [51], soluble 
Met receptor [52], and variant molecules of HGF [53]. Among the inhibitory molecules 
targeting HGF-Met pathway, NK4 has been the most extensively examined for developing a 
therapeutic approach.  
 HGF is a heterodimeric molecule composed of a 69 kDa α-chain and a 34 kDa β-chain.  
The α-chain contains the N-terminal hairpin domain and subsequent four kringle domains 
while the β-chain contains a serine protease-like domain (Fig. 3A) [5]. NK4 is composed of 
the N-terminal 447 amino acids of the α-chain, thus it contains the N-terminal hairpin 
domain and subsequent four kringle domains (thus designated NK4) [15]. NK4 binds to Met 
receptor, but does not activate the Met receptor, thereby competitively inhibiting the Met 
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receptor activation induced by HGF (Fig.3B). Because NK1 (N-terminal and the first kringle 
domains) is the minimum region for high-affinity binding to the Met receptor, NK1, NK2, 
NK3, as well as NK4, exhibit high-affinity binding to the Met receptor. It is noteworthy that 
NK1, NK2, and NK3, all variants of the α-chain containing binding domains to the Met 
receptor retain agonistic activity, not fully but in part [54-56]. Although the mechanism by 
which high-affinity binding of NK4 to the Met does not activate Met has yet determined, 
NK4 is the complete competitive antagonist for HGF.  
 Fig. 3A demonstrates antagonistic activities of NK4 on HGF-induced invasion of 
cancer cells. When human pancreatic cancer cells were co-cultured with stromal fibroblasts, 
invasion of the cells was strongly enhanced compared to that seen in the culture of cancer 
cells alone. In contrast, NK4 almost completely inhibited invasion of cancer cells in the 
co-culture system [57].  
 
5 NK4 as an Angiogenesis Inhibitor 
 Since vascular endothelial cells express the Met receptor and HGF has angiogenic 
activity, it was considered that NK4 might inhibit the angiogenic responses induced by HGF.  
However, when effects of NK4 on human vascular endothelial cells in culture were 
examined, NK4 unexpectedly inhibited proliferation and migration of endothelial cells 
enhanced by bFGF and vascular endothelial cell growth factor (VEGF), as well as by HGF 
[58]. Likewise, when a pellet containing bFGF or VEGF was implanted under the rabbit 
cornea, bFGF induced extensive angiogenesis, whereas the co-existence of NK4 with bFGF 
or VEGF in the pellet inhibited angiogenesis induced by bFGF or VEGF [58]. These results 
suggested that NK4 has an angioinhibitory as well as antagonizing action against HGF and 
the Met receptor. Because NK4 competitively inhibits biological actions of HGF through 
high-affinity binding to the Met receptor, we asked if the binding of NK4 to the Met receptor 
is involved in the antiangiogenic activity of NK4. Because the N-terminal domain in HGF is 
essential for high-affinity binding of HGF to the Met, the N-terminal domain was deleted 
from NK4. Deletion of the N-terminal domain in NK4 led to a loss of HGF-antagonist 
activity, whereas the remaining variant composed of four kringle domains retained 
antiangiogenic activity [59]. Thus, NK4 is bifunctional, as it is HGF-antagonist and an 
angiogenesis inhibitor.  
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 The binding of NK4 to the Met receptor is not involved in angioinhibitory action of 
NK4, then a question how NK4 inhibits signal transduction driven by angiogenic growth 
factors remained to be addressed. In human endothelial cells in culture, NK4 inhibited 
tyrosine phosphorylation of the Met receptor induced by HGF, whereas it did not inhibit 
tyrosine phosphorylation of the VEGF receptor-2 induced by VEGF [58]. Likewise, NK4 did 
not inhibit activation of ERK-1/2 induced by VEGF and bFGF. These results indicated that 
NK4 allowed for activation of receptors and subsequent signal transduction, at least, leading 
to activation of ERK-1/2. Taken together with the finding that the binding of NK4 to the Met 
receptor is not essential to exert angioinhibitory actions, association of NK4 to a putative 
binding molecule other than Met receptor may participate in the antiangiogenic signal 
transduction of NK4.  
 Merkulova-Rainon et al. [60] reported that the N-terminal hairpin-like domain of HGF 
did not bind to the Met receptor, whereas it inhibited angiogenic activity of VEGF, bFGF, as 
well as HGF. Because 1) these angiogenic growth factors have affinity for heparansulfate 
proteoglycans, 2) the N-terminal domain has affinity for heparansulfate proteoglycans, and 
3) the N-terminal domain inhibited binding of these growth factors to vascular endothelial 
cells, they proposed that the mechanism of anti-angiogenic activity of the N-terminal domain 
does not depend on binding to the Met receptor and that competitive inhibition of the 
N-terminal domain for binding of angiogenic growth factors to endothelial 
glycosaminoglycans may participate in angioinhibitory actions of the N-terminal domain. In 
addition to the N-terminal domain, involvement of the kringle domain in angiogenesis 
inhibition was noted. Xin et al. [61] indicated that the first kringle domain of HGF inhibited 
cell proliferation stimulated by bFGF and enhanced apoptosis in bovine aortic endothelial 
cells. Taken together, the kringle domains of NK4 are responsible for angioinhibitory activity 
of NK4, while the N-terminal domain augments anti-angiogenic activities of NK4.  
 
6 Experimental Cancer Treatment with NK4  
 Colon carcinoma represents one of the most frequently occurring cancers and the 
majority of deaths from colon cancer are due to metastasis, with the liver being the most 
frequent site of metastasis. When murine colon carcinoma cells were inoculated into the 
spleens of mice, the cancer cells metastasized to the liver and formed a number of metastatic 
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nodules [62]. In this model, the human NK4 gene was expressed predominantly in the liver. 
The number of intrahepatic metastatic nodules was inhibited by NK4 gene expression (Fig. 
4). Likewise, the mean area of each intrahepatic metastases in mice given the NK4 plasmid 
was much smaller than that in control mice (Fig. 4), indicating that hepatic expression of 
NK4 suppressed growth of metastases. Because blood vessel density in metastatic nodules 
was decreased and the number of cancer cells undergoing apoptotic cell death was enhanced 
by NK4-treatment, expression of NK4 inhibited angiogenesis in intrahepatic metastatic 
tissues, thereby inhibiting growth of hepatic metastases.  
 Histological appearances of intrahepatic metastases indicated that expression of NK4 
strongly inhibited spreading and invasion of cancer cells to surrounding hepatic tissue. In 
control mice, tyrosine-phosphorylated/activated Met (pY-Met) was detectable in colon 
cancer cells in peripheral regions of metastases (Fig. 4), whereas tyrosine phosphorylated 
Met was mostly undetectable in cancer cells in mice given the NK4 plasmid. Thus NK4 
inhibited activation of the Met receptor in colon cancer cells, thereby inhibiting their 
spreading and invasion as an HGF-antagonist. The life span of the mice was also prolonged 
by NK4 gene therapy.  
 Therapeutic effects caused by simultaneous blocking of tumor angiogenesis and Met 
receptor activation by NK4 have been also demonstrated in metastatic cancer models. When 
human pancreatic cancer cells were inoculated into the pancreas of nude mice, the pancreatic 
cancer formed a large mass and spontaneously disseminated into the peritoneal cavity four 
weeks after tumor inoculation [63]. Control mice started dying with pancreatic cancer from 
26 days post-inoculation, and all of the mice were dead within 69 days after the inoculation. 
In mice treated with NK4, 60% of mice survived for more than 70 days. When moribund 
control mice were examined, the peritoneum, diaphragm, and mesentery were occupied with 
numerous metastatic nodules, and the mean number of disseminated metastatic nodules 
reached 180. In contrast, the number of disseminated metastatic nodules was only 29 in 
NK4-treated mice. Furthermore, NK4 treatment inhibited ascites accumulation to 24.5% of 
control levels. Thus, NK4 treatment has unique and static effects on malignant behavior of 
pancreatic cancer, the result being a prolonged life span of the mice.  
 Experimental cancer treatment with NK4 protein and NK4 gene therapy have been 
given for distinct types of cancers (Table 1). NK4-treatment led to anti-invasion/metastasis, 
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anti-angiogenesis and anti-growth effects in these cancers.  
 
7 Perspectives 
 HGF has biological activities involved in dynamic tissue remodeling during 
embryogenesis and tissue regeneration. Breakdown of the extracellular matrix scaffold and 
concomitant cellular migration, mitogenesis, and morphogenesis driven by the HGF-Met 
system make way for construction and reconstruction of tissues through 
epithelial-mesenchymal interactions, fundamental tissue interactions involved in dynamic 
morphogenesis and regeneration. However, a definitive difference between 
epithelial-mesenchymal and tumor-stromal interactions is that the expression and functions 
of mediators and their receptors participating in the former interactions are tightly regulated; 
once normal tissue architectures are constructed or reconstructed, their expression and 
functions become quiescent in epithelial-mesenchymal interactions. Elucidation of the 
negative regulatory mechanisms for HGF-Met pathway and their loss-of-functions in cancers 
may lead to unique understanding of malignant progression of cancers.  
 Since both chemo and radiotherapies are based on the concept to directly kill cancer 
cells, these therapies have severe side effects and the result is reduction in quality of life 
and/or in decrease in immune responses. The surgical removal of cancer after early detection 
can be associated with disease-free survival of patients in case of some malignant cancers, 
yet surgical treatment often results in incomplete removal of cancer cells, allowing invasion 
and metastasis of cancer cells. HGF and its partner Met play a definitive role in 
tumor-stromal interactions, particularly leading to invasive and metastatic cancers. A 
therapeutic strategy targeting the HGF-Met axis is based on the suppression of the intrinsic 
characteristics of malignant tumors, i.e., invasion and metastasis. Therapeutic approaches 
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Table 1. Therapeutic studies on NK4 in experimental models. 
                  
 
Type of tumor Inoculation site Recombinant NK4 protein or Sites of delivery References
(species of tumor) of tumor cells NK4 gene expression 
               
 
Breast cancer Subcutaneous Protein Subcutaneous near [64]  
(human)    tumor  
 
Breast cancer Subcutaneous Protein Subcutaneous, near tumor [58]  
(murine)     
 
Colon cancer  Spleen Gene expression by plasmid Intravenous [62] 
(murine) 
 Cervical vein Gene expression by adenovirus Intraperitoneal [65]  
 
 Subcutaneous Gene expression by adenovirus Intratumoral, combination [66]  
   with dendritic cells 
 
 Subcutaneous Gene expression by plasmid Intravenous [67] 
 
 Subcutaneous Stable gene expression Expression by cancer cells [68, 69] 
 
 Intravenous Gene expression by adenovirus Expression in mesenchymal  [70] 
   stem cells 
 
Colon cancer Subcutaneous Gene expression by adenovirus Intratumoral [71] 
(human)  
 
Gallbladder cancer Subcutaneous Protein Subcutaneous, near tumor [72]  
(human)   
 Intraperitoneal Gene expression by adenovirus Intraperitoneal [73]  
     
 
Gastric cancer Subcutaneous Stable gene expression Expression by cancer [74]  
(human)  or adenovirus cells or intratumoral 
 
 Subcutaneous Gene expression by adenovirus Intratumoral [75]  
 
 Intraperitoneal Gene expression by adenovirus Intraperitoneal, combination [76]  
   with cisplatin 
 
 Intraperitoneal Gene expression by adenovirus Intraperitoneal [77] 
 
 Intraperitoneal Gene expression by liposome Intraperitoneal [78] 
 
Glioblastoma Orthotopic Protein Intratumoral [79]  
(human) 
 
Hepatoma Subcutaneous Gene expression by adenovirus Intratumoral [80] 
(human)  
 Subcutaneous Gene expression by adenovirus Intratumoral or intravenous [81] 
 or orthotopic  
 
Lung cancer Subcutaneous Protein Subcutaneous, near tumor [58]  
(murine)  
 Subcutaneous Gene expression by adenovirus Intratumoral, combination [66]  
   with dendritic cells 
 
 Subcutaneous Gene expression by plasmid Subcutaneous, [82]  
  in cationized gelatin around tumor  
 
Lung cancer  Subcutaneous Gene expression by adenovirus Intratumoral or [65]  
(human)    intraperitoneal  
 
 Subcutaneous Cancer cell-specific gene Intratumoral [83]  
  expression by adenovirus   
 
Lymphoma Subcutaneous Gene expression by adenovirus Intratumoral, combination [66]  
(murine)   with dendritic cells 
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Melanoma Subcutaneous Gene expression by adenovirus Intratumoral, combination [66]  
(murine)   with dendritic cells  
 
Ovarian cancer Intraperitoneal Stable gene expression Expression by cancer cells [85]  
(human)     
 
Pancreatic cancer Orthotopic Protein Intraperitoneal [63]  
(human)    
 
 Intraperitoneal Gene expression by adenovirus Intraperitoneal [86, 87]  
 
 Orthotopic Stable gene expression Expression by cancer cells [88]  
 
 Subcutaneous Protein released by cell sheets Implantation of cell sheet [89]  
 
 Orthotopic Gene expression by adenovirus Peritumoral, combination [90] 
   with gemcitabine 
 
Prostate cancer Subcutaneous Protein Subcutaneous, [91]  
(human)   near tumor 
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Figure Legends 
 
Fig. 1. Cancer cell invasion induced by HGF (A) and the crosstalk between tumor 
cells and stromal cells mediated by HGF-inducers and HGF (B). In (A), human 
cholangiocarcinoma cells and mouse lung carcinoma cells were cultured in collagen 
gel in the absence or presence of HGF or epidermal growth factor (EGF).  
 
Fig. 2. Negative regulation of the Met receptor activation through cell-cell contact 
(A) and the juxtamembrane Ser985 phosphorylation (B). In hepatocytes in tight 
cell-cell contact, expression of LAR is up-regulated and LAR protein tyrosine 
phosphatase inactivates/dephosphorylates Met [36]. Ser985 in the juxtamembrane 
domain of Met is phosphorylated by protein kinase-C (PKC) and dephosphorylated 
by protein phosphatase-2A (PP-2A). When Ser985 is phosphorylated, tyrosine 
phosphorylation of Met is suppressed [38]. Loss-of-function in these negative 
regulatory mechanisms in the Met is potentially considerable in cancer cells.  
 
Fig. 3. Structure and biological activity of NK4 as a competitive HGF-antagonist. (A) 
Schematic structures of HGF and NK4. NK4 was originally isolated from proteolytic 
fragments of HGF [15]. (B) Outline for inhibitory action of NK4. NK4 binds to Met but 
does not activate Met, thereby competitively inhibiting activation of Met induced by 
HGF. (C) Inhibitory effect of NK4 on invasion of pancreatic cancer cells. Cancer cells 
were cultured on Matrigel basement membrane components in the absence or 
presence of stromal fibroblasts and the number of invading cells was determined.  
 
Fig. 4. Inhibition of metastasis and invasive growth of colon cancer by NK4 in mice 
[62]. In the liver metastasis model of colon cancer, NK4 gene therapy inhibited 
hepatic metastasis (inset photographs) and growth of hepatic metastases (middle 
graph). Likewise, NK4 gene therapy inhibited tyrosine phosphorylation of the Met in 
cancer cells in hepatic metastases (lower panels) and this was associated with 
inhibition of spreading and invasion of cancer cells into hepatic tissue.  




